OCUL Ocular Therapeutix Inc.

4.23
-0.13  -3%
Previous Close 4.36
Open 4.27
Price To Book 7.05
Market Cap 181,200,417
Shares 42,836,978
Volume 808,300
Short Ratio
Av. Daily Volume 847,998

NewsSee all news

  1. Ocular (OCUL) Gets FDA Nod for Label Expansion of Dextenza
  2. Bulls And Bears Of The Week: Tyson, Tesla, Crocs And More
  3. FDA OKs Expanded Indication For Ocular Therapeutix Eye Pain Drug Months Ahead Of Schedule
  4. Ocular Therapeutix™ Announces FDA Approval of Supplemental New Drug Application (sNDA) for DEXTENZA® (0.4 Dexamethasone Intracanalicular Insert for Ophthalmic Use) for the Treatment of Ocular Inflammation Following Ophthalmic Surgery
  5. Ocular Therapeutix Inc (OCUL) President & CEO Antony C. Mattessich Bought $112,400 of Shares

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

FDA Approval June 21, 2019.
DEXTENZA
Post-surgical ocular inflammation and pain
Phase 3 trial did not meet primary endpoint - June 2016. Additional Phase 3 trial to be initiated pending data from a non-significant risk device study to be initiated in 2017.
DEXTENZA
Allergic conjunctivitis
Phase 3 data May 20, 2019 did not meet primary endpoint.
OTX-TP
Glaucoma and ocular hypertension
FDA approval announced December 3, 2018.
DEXTENZA
Ocular inflammation and pain following cataract surgery
Phase 2 complete. Assessing plans forward.
DEXTENZA
Dry Eye Disease
Phase 1 initial data released April and May 2019.
OTX-TIC
Glaucoma and ocular hypertension
Phase 1 dosing of first patient announced February 20, 2019.
OTX-TKI
Wet Age-related Macular Degeneration (AMD)

Latest News

  1. Ocular (OCUL) Gets FDA Nod for Label Expansion of Dextenza
  2. Bulls And Bears Of The Week: Tyson, Tesla, Crocs And More
  3. FDA OKs Expanded Indication For Ocular Therapeutix Eye Pain Drug Months Ahead Of Schedule
  4. Ocular Therapeutix™ Announces FDA Approval of Supplemental New Drug Application (sNDA) for DEXTENZA® (0.4 Dexamethasone Intracanalicular Insert for Ophthalmic Use) for the Treatment of Ocular Inflammation Following Ophthalmic Surgery
  5. Ocular Therapeutix Inc (OCUL) President & CEO Antony C. Mattessich Bought $112,400 of Shares
  6. Does Market Volatility Impact Ocular Therapeutix, Inc.'s (NASDAQ:OCUL) Share Price?
  7. Options Traders Expect Huge Moves in Ocular (OCUL) Stock
  8. Ocular Therapeutix™ to Present at Three Upcoming Investor Conferences
  9. Ocular Therapeutix™ Announces Receipt of C-Code and Pass-Through Payment Status for DEXTENZA®
  10. Edited Transcript of OCUL earnings conference call or presentation 10-May-19 12:30pm GMT
  11. Ocular's Glaucoma Drug Study Fails to Meet Primary Endpoint
  12. Raymond James Downgrades Ocular Therapeutix, Remains Bullish On Pipeline
  13. Chevron, Sprint, Ocular Therapeutix, and More: Why These Stocks Are in the Spotlight
  14. Ocular Therapeutix™ Announces Topline Results of Phase 3 Clinical Trial of OTX-TP for the Treatment of Glaucoma
  15. Ocular Therapeutix (OCUL) Reports Q1 Loss, Tops Revenue Estimates
  16. Ocular Therapeutix: 1Q Earnings Snapshot
  17. Ocular Therapeutix™ Reports First Quarter 2019 Financial Results and Business Update
  18. Analysts Estimate Ocular Therapeutix (OCUL) to Report a Decline in Earnings: What to Look Out for
  19. Ocular Therapeutix™ To Report First Quarter 2019 Financial Results
  20. Ocular Therapeutix Announces DEXTENZA® (dexamethasone ophthalmic insert) Recommended for Unique J-Code by CMS